GSK invests Rs 203 mn in ayurvedic manufacturing facility

Embarking on yet another milestone, GlaxoSmithKline Consumer Healthcare – Sri Lanka, (GSK) launched the new local manufacturing facility for Eno (Ayurvedic powder for acidity) and Iodex (Ayurvedic Balm) with an investment of Rs 203 million , re-affirming its commitment to the Sri Lankan economy.

Basil Rajapaksa, Minister of Economic Development commissioning the new manufacturing facility

This comes following the commission of GSK’s manufacturing facility for Panadol tablets in April 2012, with an investment of Rs 217 million. The new Eno and Iodex manufacturing facility is amongst the largest state of the art ayurvedha production facilities in Sri Lanka and conforms to GSK’s strictest global quality standards; a testament to GSK’s promise to its community to help people do more, feel better and live longer.”

The new facilities will be located adjacent to its present pharmaceutical operation in Moratuwa and will have over 65 employees, making a contribution to the area’s employment scenario. The new facility was declared open by Basil Rajapaksa, Minister for Economic Development in the presence of many dignitaries and GSK personnel. Commenting at the launch ceremony, Managing Director of GSK Consumer Healthcare Sri Lanka, T.S Dayanand, said “At a time when Sri Lanka is poised for growth in all economic sectors, GSK is proud to unveil another initiative to support ‘Nation Building’ by commissioning the Eno and Iodex plants.

“ We strongly believe that this investment will further strengthen the ayurvedic manufacturing landscape in Sri Lanka. GSK employs over 500 people and works closely with over 200 business partners in Sri Lanka, thereby touching lives of numerous people.

We will continue to live up to our vision of improving the quality of human life by enabling people to do more, feel better and live longer.”

GlaxoSmithKline Consumer Healthcare – Sri Lanka is part of GlaxoSmithKline PLC. – one of the world’s leading research-based pharmaceutical and healthcare companies operating in 117 countries that is committed to improving the quality of human life by enabling people to do more, feel better and live longer.